Bribery Trial Testimony Focuses on Melgen’s Billing for Lucentis

October 6, 2017: By Joan McKenna

legal issuesTestimony in the fifth week of a federal bribery trial against Sen. Robert Menendez, D-New Jersey, and retina specialist Salomon Melgen, MD, focused on Melgen’s billing practices for Lucentis.

Prosecutors in the case claim that Menendez tried to intervene in Melgen’s $8.9 million billing dispute with Medicare by asking senior health officials to consider whether billing policies should be changed.

Menendez received gifts and campaign contributions from Melgen in return, US attorneys allege.

The Centers for Medicare and Medicaid Services (CMS) accused Melgen of overbilling Medicare $8.9 million in 2007 and 2008 by charging the government per eye patient, even though he repackaged single-use Lucentis vials into multiple syringes to treat several patients in a practice called multidosing. Medicare’s policy is to reimburse doctors per vial.

The cost of Lucentis in the US is about $1,900 per vial. A single-use vial holds extra solution, which Melgen used to treat two or three other patients, rather than throwing away potentially thousands of dollars in product. At issue in the case is the fact that he sought Medicare reimbursement for the number of patients treated rather than the far lower number of Lucentis vials used.

In May 2016, Melgen’s attorneys argued before a federal judge that dose splitting is common throughout medicine and Medicare would have paid $1,900 per injection if Melgen used a fresh vial for each patient.

Witnesses testifying for the prosecution Oct. 3 included former CMS head Marilyn Tavenner, who said she was not aware of any other doctor billing Medicare in the way Melgen did, according to The Associated Press.

Menendez met separately with Tavenner and former health secretary Kathleen Sebelius in 2012, asking them to reconsider the billing policy, they both testified. They declined to do so.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023